MLTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MoonLake Immunotherapeutics (MLTX) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including favorable regulatory progress, increasing analyst price targets, and institutional buying. Despite some technical weakness, the long-term growth potential outweighs short-term volatility.
The technical indicators show a bearish trend with the MACD histogram below 0 (-0.266) and negatively contracting, RSI at 37.125 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 16.435).
Regulatory progress for sonelokimab with a clear FDA approval path.
Multiple analyst upgrades with significant price target increases (e.g., Rothschild raised to $40, Clear Street to $70).
Institutional buying by Cormorant Asset Management, increasing its stake to 2.65%.
Goldman Sachs maintains a Sell rating, citing doubts about sonelokimab's approvability.
Technical indicators suggest short-term bearish momentum.
In Q4 2025, the company reported a net income improvement of 36.89% YoY to -$62.43M and an EPS increase of 27.78% YoY to -0.92. However, revenue remains at $0, indicating the company is still in the pre-revenue stage.
The majority of analysts maintain a Buy rating with significant price target increases. Rothschild upgraded the stock to Buy with a $40 target, citing regulatory clarity. Clear Street raised its target to $70, highlighting confidence in sonelokimab's potential. Goldman Sachs remains bearish with a $11 target, citing concerns about approvability.
